PALO ALTO, California, Aug. 21, 2018 /PRNewswire/ -- Varian's (NYSE: VAR) president and chief executive officer, Dow R. Wilson,has joined the Board of Directors of the US-India Strategic Partnership Forum (USISPF). Mr. Wilson is among a group of prominent global business leaders advising USISPF on its efforts to strengthen the strategic relationship between the U.S. and
"Collaborating with the USISPF and now joining its Board is an extension of Varian's long commitment to working closely with our partners in India to develop innovative cancer care solutions in the global fight against cancer," said Wilson. "I look forward to sharing Varian's experience and insights with my fellow Board members as we assist USISPF in achieving its goals."
"Mr. Wilson brings a wealth of global business experience to the organization and we are proud to welcome him to the USISPF Board," said Dr. Mukesh Aghi, president and chief executive officer of USISPF. "We look forward to his contributions as we work towards strengthening business ties between the U.S. and India."
The US-India Strategic Partnership Forum is committed to creating the most powerful strategic partnership between the U.S. and India. Promoting bilateral trade is an important part of its work, but its mission reaches further. It is about business and government coming together in new ways to create meaningful opportunities that have the power to change the lives of citizens. Headquartered in Washington, D.C., USISPF has offices in New York, Silicon Valley, Mumbai, and New Delhi. For more details, please visit http://usispf.org/. You can also follow USISPF on LinkedIn, Twitter and Facebook.
About Varian Varian is a leader in developing and delivering cancer care solutions and is focused on creating a world without fear of cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,500 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.
Mark PlungyDirector, Public Relations+1 (650) 424-5630 email@example.com
Investor Relations Contact
J. Michael BruffSenior Vice President, Investor Relations+1 (650) 424-5163 firstname.lastname@example.org
Subscribe to our Free Newsletters!
DOOR syndrome is a rare genetic disorder marked by deafness, short or absent fingernails, abnormal ...
Are you gluten intolerant? Stay away from gluten allergy and celiac disease by shifting to ...
Moxetumomab pasudotox-tdfk is used to treat hairy cell leukemia (a form of chronic lymphocytic ...View All